
    
      This is a multicenter, randomized, double-blind, placebo-controlled, 34-week, cross-over
      study, with a Treatment Period of approximately 26 weeks under the Original Crossover Design
      or, if applicable, a 21-week parallel study, with a Treatment Period of approximately 14
      weeks under the Contingent Parallel Design.
    
  